BAYER AG-REG (BAYN.DE) Stock Fundamental Analysis

FRA:BAYN • DE000BAY0017

45.985 EUR
+0.3 (+0.65%)
Last: Feb 13, 2026, 05:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

BAYN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. BAYN has a bad profitability rating. Also its financial health evaluation is rather negative. BAYN has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • BAYN had positive earnings in the past year.
  • In the past year BAYN had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BAYN reported negative net income in multiple years.
  • Each year in the past 5 years BAYN had a positive operating cash flow.
BAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFBAYN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

1.2 Ratios

  • BAYN has a Return On Assets of -0.19%. This is in the lower half of the industry: BAYN underperforms 69.09% of its industry peers.
  • BAYN has a Return On Equity of -0.67%. This is in the lower half of the industry: BAYN underperforms 69.09% of its industry peers.
  • BAYN has a Return On Invested Capital of 1.80%. This is in the lower half of the industry: BAYN underperforms 69.09% of its industry peers.
  • BAYN had an Average Return On Invested Capital over the past 3 years of 5.51%. This is significantly below the industry average of 14.21%.
Industry RankSector Rank
ROA -0.19%
ROE -0.67%
ROIC 1.8%
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)5.51%
ROIC(5y)N/A
BAYN.DE Yearly ROA, ROE, ROICBAYN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

  • Looking at the Operating Margin, with a value of 4.20%, BAYN is doing worse than 67.27% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BAYN has declined.
  • BAYN's Gross Margin of 56.35% is on the low side compared to the rest of the industry. BAYN is outperformed by 70.91% of its industry peers.
  • BAYN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 4.2%
PM (TTM) N/A
GM 56.35%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
BAYN.DE Yearly Profit, Operating, Gross MarginsBAYN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BAYN is destroying value.
  • The number of shares outstanding for BAYN remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for BAYN remains at a similar level compared to 5 years ago.
  • Compared to 1 year ago, BAYN has an improved debt to assets ratio.
BAYN.DE Yearly Shares OutstandingBAYN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
BAYN.DE Yearly Total Debt VS Total AssetsBAYN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • Based on the Altman-Z score of 1.03, we must say that BAYN is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of BAYN (1.03) is worse than 78.18% of its industry peers.
  • BAYN has a debt to FCF ratio of 10.07. This is a negative value and a sign of low solvency as BAYN would need 10.07 years to pay back of all of its debts.
  • BAYN's Debt to FCF ratio of 10.07 is on the low side compared to the rest of the industry. BAYN is outperformed by 63.64% of its industry peers.
  • A Debt/Equity ratio of 1.11 is on the high side and indicates that BAYN has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.11, BAYN is doing worse than 69.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.07
Altman-Z 1.03
ROIC/WACC0.26
WACC6.96%
BAYN.DE Yearly LT Debt VS Equity VS FCFBAYN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • BAYN has a Current Ratio of 1.14. This is a normal value and indicates that BAYN is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.14, BAYN is not doing good in the industry: 65.45% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.71 indicates that BAYN may have some problems paying its short term obligations.
  • BAYN has a worse Quick ratio (0.71) than 74.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.71
BAYN.DE Yearly Current Assets VS Current LiabilitesBAYN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • BAYN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.72%.
  • BAYN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.27% yearly.
  • The Revenue has decreased by -1.87% in the past year.
  • BAYN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.37% yearly.
EPS 1Y (TTM)-8.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%137.5%
Revenue 1Y (TTM)-1.87%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.09%

3.2 Future

  • Based on estimates for the next years, BAYN will show a small growth in Earnings Per Share. The EPS will grow by 3.51% on average per year.
  • Based on estimates for the next years, BAYN will show a small growth in Revenue. The Revenue will grow by 1.22% on average per year.
EPS Next Y-5.02%
EPS Next 2Y-1.64%
EPS Next 3Y1.75%
EPS Next 5Y3.51%
Revenue Next Year-1.56%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.49%
Revenue Next 5Y1.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BAYN.DE Yearly Revenue VS EstimatesBAYN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B 50B
BAYN.DE Yearly EPS VS EstimatesBAYN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.61, the valuation of BAYN can be described as reasonable.
  • BAYN's Price/Earnings ratio is rather cheap when compared to the industry. BAYN is cheaper than 96.36% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BAYN to the average of the S&P500 Index (27.97), we can say BAYN is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.41, which indicates a very decent valuation of BAYN.
  • Based on the Price/Forward Earnings ratio, BAYN is valued cheaply inside the industry as 92.73% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.96, BAYN is valued rather cheaply.
Industry RankSector Rank
PE 8.61
Fwd PE 9.41
BAYN.DE Price Earnings VS Forward Price EarningsBAYN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BAYN indicates a somewhat cheap valuation: BAYN is cheaper than 65.45% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, BAYN is valued cheaply inside the industry as 90.91% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.48
EV/EBITDA 12.36
BAYN.DE Per share dataBAYN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.64%
EPS Next 3Y1.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • BAYN has a yearly dividend return of 0.25%, which is pretty low.
  • BAYN's Dividend Yield is slightly below the industry average, which is at 1.94.
  • Compared to an average S&P500 Dividend Yield of 1.79, BAYN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.25%

5.2 History

  • The dividend of BAYN decreases each year by -45.34%.
Dividend Growth(5Y)-45.34%
Div Incr Years0
Div Non Decr Years3
BAYN.DE Yearly Dividends per shareBAYN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

  • BAYN has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-65.15%
EPS Next 2Y-1.64%
EPS Next 3Y1.75%
BAYN.DE Yearly Income VS Free CF VS DividendBAYN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B -10B

More info and screens

Find the best dividend stocksShow peers with best dividend

BAYER AG-REG

FRA:BAYN (2/13/2026, 5:36:15 PM)

45.985

+0.3 (+0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)02-25
Inst Owners49.57%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap45.18B
Revenue(TTM)45.87B
Net Income(TTM)-198.00M
Analysts74.29
Price Target42.36 (-7.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.25%
Yearly Dividend0.13
Dividend Growth(5Y)-45.34%
DP-65.15%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.52%
Min EPS beat(2)45.89%
Max EPS beat(2)71.16%
EPS beat(4)4
Avg EPS beat(4)30.58%
Min EPS beat(4)1.86%
Max EPS beat(4)71.16%
EPS beat(8)7
Avg EPS beat(8)18.15%
EPS beat(12)9
Avg EPS beat(12)7.9%
EPS beat(16)12
Avg EPS beat(16)7.93%
Revenue beat(2)0
Avg Revenue beat(2)-2.53%
Min Revenue beat(2)-2.63%
Max Revenue beat(2)-2.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.06%
Min Revenue beat(4)-2.63%
Max Revenue beat(4)1.79%
Revenue beat(8)2
Avg Revenue beat(8)-1.69%
Revenue beat(12)2
Avg Revenue beat(12)-2.67%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)23.31%
PT rev (3m)45.7%
EPS NQ rev (1m)11.15%
EPS NQ rev (3m)-30.33%
EPS NY rev (1m)0.15%
EPS NY rev (3m)1.58%
Revenue NQ rev (1m)0.54%
Revenue NQ rev (3m)-1.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.19%
Valuation
Industry RankSector Rank
PE 8.61
Fwd PE 9.41
P/S 0.98
P/FCF 11.48
P/OCF 6.72
P/B 1.53
P/tB N/A
EV/EBITDA 12.36
EPS(TTM)5.34
EY11.61%
EPS(NY)4.89
Fwd EY10.62%
FCF(TTM)4.01
FCFY8.71%
OCF(TTM)6.84
OCFY14.88%
SpS46.69
BVpS30.11
TBVpS-18.8
PEG (NY)N/A
PEG (5Y)N/A
Graham Number60.14
Profitability
Industry RankSector Rank
ROA -0.19%
ROE -0.67%
ROCE 2.56%
ROIC 1.8%
ROICexc 2%
ROICexgc 6.8%
OM 4.2%
PM (TTM) N/A
GM 56.35%
FCFM 8.58%
ROA(3y)-0.5%
ROA(5y)-1.93%
ROE(3y)-2.08%
ROE(5y)-7.52%
ROIC(3y)5.51%
ROIC(5y)N/A
ROICexc(3y)6.21%
ROICexc(5y)N/A
ROICexgc(3y)25.79%
ROICexgc(5y)N/A
ROCE(3y)7.82%
ROCE(5y)N/A
ROICexgc growth 3Y-23.46%
ROICexgc growth 5Y-1.27%
ROICexc growth 3Y-13.2%
ROICexc growth 5Y2.54%
OM growth 3Y-18.1%
OM growth 5Y-4.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.21%
GM growth 5Y-1.81%
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 10.07
Debt/EBITDA 5.32
Cap/Depr 66.1%
Cap/Sales 6.08%
Interest Coverage 1.09
Cash Conversion 109.39%
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 0.71
Altman-Z 1.03
F-Score5
WACC6.96%
ROIC/WACC0.26
Cap/Depr(3y)34.81%
Cap/Depr(5y)41.62%
Cap/Sales(3y)5.85%
Cap/Sales(5y)5.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.72%
EPS 3Y-8.12%
EPS 5Y-5.27%
EPS Q2Q%137.5%
EPS Next Y-5.02%
EPS Next 2Y-1.64%
EPS Next 3Y1.75%
EPS Next 5Y3.51%
Revenue 1Y (TTM)-1.87%
Revenue growth 3Y1.87%
Revenue growth 5Y1.37%
Sales Q2Q%-3.09%
Revenue Next Year-1.56%
Revenue Next 2Y-0.38%
Revenue Next 3Y0.49%
Revenue Next 5Y1.22%
EBIT growth 1Y-2.82%
EBIT growth 3Y-16.56%
EBIT growth 5Y-3.03%
EBIT Next Year65.28%
EBIT Next 3Y21.41%
EBIT Next 5Y12.99%
FCF growth 1Y873.08%
FCF growth 3Y22.16%
FCF growth 5Y-3.69%
OCF growth 1Y161.6%
OCF growth 3Y12.83%
OCF growth 5Y-2.09%

BAYER AG-REG / BAYN.DE FAQ

What is the fundamental rating for BAYN stock?

ChartMill assigns a fundamental rating of 2 / 10 to BAYN.DE.


What is the valuation status of BAYER AG-REG (BAYN.DE) stock?

ChartMill assigns a valuation rating of 6 / 10 to BAYER AG-REG (BAYN.DE). This can be considered as Fairly Valued.


How profitable is BAYER AG-REG (BAYN.DE) stock?

BAYER AG-REG (BAYN.DE) has a profitability rating of 2 / 10.


How financially healthy is BAYER AG-REG?

The financial health rating of BAYER AG-REG (BAYN.DE) is 1 / 10.


How sustainable is the dividend of BAYER AG-REG (BAYN.DE) stock?

The dividend rating of BAYER AG-REG (BAYN.DE) is 0 / 10 and the dividend payout ratio is -65.15%.